perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Molecular insights of β -lactams resistance in *Klebsiella pneumoniae* isolates with focus on multidrug 1 resistance and virulence from colonization samples 2

Lavouisier F.B. Nogueira ^{1, 2}[#], Marco A.F Clementino ^{1, 2}[#], Marília S. Maia ^{1, 2}[#], Ila F.N. Lima ³, Jorge L.N. Rodrigues ³, Luciana V.C. Fragoso ³, Glairta S. Costa ³, Jose Q.S. Filho ¹, Alexandre Havt ^{1, 2}, Deiziane V.S. Costa ⁴, José K. Sousa ¹, Lyvia M.V.C. Magalhães ¹, Dilza Silva ⁵, Nicholas E. Sherman ⁵ and Aldo A.M. Lima ^{1, 2}*

- ¹ Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.
- ² Postgraduate Medical Microbiology Program, Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.
- ³ Hospital Universitário Walter Cantídio, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.
- ⁴ Infectious Diseases and International Health, University of Virginia, Charlottesville, VA 22908.
- ⁵ Biomolecular Analysis Facility, School of Medicine, University of Virginia, Charlottesville, VA 22908.
- * Correspondence: <u>alima@ufc.br</u>
- [#] These authors contributed equally to this work.

e-Mails: lavouisier@gmail.com, mclementino@ufc.br, mmaia800@gmail.com, ila.lima@ebserh.gov.br, 18 jorge1207@gmail.com, luciana.vladia@gmail.com, glairta14@gmail.com, jquirinof@gmail.com, ah- 19 avt@ufc.br, deiziane2009@gmail.com, kleybson.jks@alu.ufc.br, lyviacarneiro@ufc.br, xjb8bf@virginia.edu, 20 nes3f@virginia.edu, alima@ufc.br. 21

Abstract: Klebsiella pneumoniae is associated with high resistance to antimicrobials and is common in iso-22 lates from colonization and nosocomial infections. The study aims to detect resistance genes belonging to 23 the *bla* family and investigate metabolic pathways in K. pneumoniae isolates. Genes from the subfamilies 24 included: blaSHV, blaTEM, blaNDM, blaKPC, blaGES, blaCTX-M and relevant variants of the blaOXA sub-25 family. Mass spectrometry data were acquired on the Orbitrap IDX spectrometer (Thermo) connected to the 26 Vanquish UPLC system. Isolates from 122 K. pneumoniae samples were collected from 04/23/2019 to 27 05/29/2021. A high prevalence of resistance to penicillins, cephalosporins and carbapenems was found 28 among the isolates. The identified genotypic profile showed a high prevalence of genes belonging to Ambler's 29 classes of beta-lactamases A, B and D. In the metabolomic study, the N-fructosyl isoleucine metabolite was 30 identified increased in multidrug-resistant (MDR) strains of K pneumoniae compared to strains susceptible to 31 antimicrobials. In conclusion, the assays developed were efficient in detecting the main genes of the bla 32 family of resistance in K. pneumoniae. The use of the pentose phosphate metabolic pathway suggests the 33 regulation of bacterial growth, virulence, and colonization in MDR K. pneumoniae strains. 34

Keywords: Antimicrobial resistance; multidrug-resistant; β-lactamases; qPCR; molecular diagnosis; virulence; *Klebsiella pneumoniae*.

37

3

4

5

6

7

8

9

10

11

12

13

14

15

16 17

1. Introduction

Bacterial resistance to antimicrobial agents is a global public health problem that leads to an increase 40 in the cost of treatment, length of stay and morbidity and mortality of hospitalized patients, especially in 41 intensive care units (ICU) [1, 2]. In this sense, understanding the emergency mechanisms of regulation and 42 dissemination of resistance to antimicrobial agents in the pathogenesis of bacterial colonization and/or infec-43 tion can be of critical importance in preventing and controlling this dissemination. 44

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Klebsiella pneumoniae is a gram-negative γ -proteobacteria microorganism belonging to the *Entero-* 45 bacteriales family, and is known to be opportunistic, carrying several virulence factors and capable of 46

39

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

accumulating resistance genes to various classes of antimicrobials. It is commonly related to cases of colo-47 nization and/or healthcare-associated infections (HAIs) and has been identified as an etiological agent in 48 pneumonia, urinary tract infections (UTI), soft tissue and surgical wound infections, bacteremia, and sepsis 49 [3]. It is estimated that K. pneumoniae is responsible for approximately 10% of all cases of nosocomial infec-50 tions, and of these, 32.8% are caused by strains resistant to multiple antimicrobial drugs. However, studies 51 indicate that the rate of isolated strains presenting resistance to antimicrobials has increased over the years 52 [4, 5]. K. pneumoniae has been associated with the ability to overcome colonization resistance imposed by 53 the gastrointestinal microbiota [6] and has been reported as an emerging multidrug-resistant strain and of 54 emergency priority by the World Health Organization (WHO) for the development of new therapies [7]. Epi-55 demiological data have demonstrated that K. pneumoniae can translocate from the gastrointestinal tract to 56 other sterile sites of the same host or other patients through the fecal-oral route. Despite the well-established 57 clinical relevance, little is known about the mechanisms behind the emergence and dissemination of multi-58 drug-resistant (MDR) K. pneumoniae strains [8]. 59

One of the most likely causes of the increasingly frequent appearance of bacterial strains resistant to 60 one or more antibiotics is the excessive and sometimes incorrect use of antimicrobials. The relatively long 61 time required to identify the pathogen by traditional methods, as well as for the results of the antimicrobial 62 susceptibility test (AST), forces the clinician to use broad-spectrum drugs empirically, increasing selective 63 pressure, the which ends up benefiting pathogens genetically capable of adapting to the adverse environment 64 [1, 9]. A possible answer to reduce the time needed to obtain a resistance profile is the development of 65 molecular methodologies, which aim to identify the genetic profile of resistance of the agent causing the 66 infection. Molecular laboratory tests could not only make the identification of resistance faster, but they could 67 also be more susceptible and useful in the case of colonization and/or infections caused by fastidious micro-68 organisms, giving the clinician a timely response to reduce the empirical use of antimicrobial drugs [10]. Beta-69 lactams are the class of antimicrobials most affected by resistance in general, which is conferred in gram-70 negatives, mainly by the bla gene family [11, 12, 13]. Therefore, we seek to develop a molecular assay, 71 capable of identifying all variants of the most relevant genes of the bla family, these being: blaSHV, blaTEM, 72 blaNDM, blaKPC, blaGES, blaCTX-M. In addition to variants with epidemiology most relevant components 73 of the bla-OXA gene. Thus, creating a set of primers capable of detecting the presence of hundreds of re-74 sistance genes with a reduced number of reactions. 75

In this study, we identified the phenotypic and genotype profile of genes from the bla family of β -76 lactamases in MDR K. pneumoniae strains isolated from patients admitted to the ICU in Fortaleza-CE, Brazil. 77 Furthermore, we investigated the metabolomic modulation associated with virulence in MDR strains of K. 78 pneumoniae compared with strains susceptible to antimicrobial agents of K. pneumoniae, both isolated from 79 colonization sites. 80

81

82

2. Materials and Methods

2.1 Obtaining bacterial isolates and identification.

This study was a cohort prospective design. It was approved by the Brazilian National Research Ethics 83 Commission (no. 03300218.2.0000.5054), and carried out in the University Hospital, Federal University of 84 Ceará, Fortaleza, Northeastern Brazil. For the following study, samples were collected to investigate coloni-85 zation sites, as part of the clinical investigation of patients admitted to the ICU of a tertiary care health unit in 86 the city of Fortaleza-CE. We included those microorganisms that were identified as gram-negative bacteria, 87 resistant to two or more groups of antimicrobial agents, including subclasses of β-lactams, fluoroquinolones, 88

aminoglycosides, macrolides, and glycopeptides. Bacterial isolates were selected from bloodstream, as well 89 as other sites considered noble, such as cerebrospinal fluid (CSF), pleural, peritoneal, pericardial, synovial, 90 among others. Bacterial isolates from urinary tract, bronchoalveolar lavage, tracheal aspirate, sputum, ab-91 scess drainage, surgical wounds, among others, were also selected. Culture of fragments, such as skin, 92 organs, and bones as well as rectal swab culture for surveillance, without apparent infection also had their 93 bacterial isolates selected. With the aim of diagnosing potential etiological agents, blood culture samples and 94 other noble liquids were inoculated in specific bottles and incubated in the BacT/Alert® 3D equipment (Bio-95 Mérieux, Marcy l'Etoile, France). The other biological materials were culture using a qualitative or quantitative 96 sowing technique, to obtain isolated colonies. The plates were incubated at $37 \pm 2^{\circ}$ C for 18-24 hours [14]. 97

The bacterial isolates were identified and tested for their susceptibility to antimicrobials using the automated VITEK® 2 Compact method (BioMérieux, Marcy l'Etoile, France), according to the manufacturer's precommendations. Minimum inhibitory concentrations were interpreted according to the Clinical and Laboratory Standards Institute (CLSI). For quality control of sensitivity tests, strains from the American Type Culture included in the study.

2.2 Extraction of bacterial DNA.

To extract the genetic material, the Wizard Genomic DNA Purification extraction and purification kit (Promega, Madison, USA) was used, according to the manufacturer's recommendations.

After extraction, all samples were then quantified by spectrophotometry using the NanoDropTM 2000 107 (Thermo Fisher Scientific, Waltham, Massachusetts, USA) and stored in a -80°C freezer until used in the experiments.

2.3 Selection of genes used in the study and obtaining FASTA sequences.

For greater coverage of the genetic profile of resistance to β -lactams in gram negatives, genes with 111 relevant prevalence epidemiology, belonging to the *bla* gene family, were part of the study, and these included the genes: *blaSHV*, *blaTEM*, *blaNDM*, *blaKPC*, *blaGES*, *blaCTX-M* and *blaOXA*. The sequences 113 used were obtained through the Comprehensive Antibiotic Resistance Database (CARD) platform, which 114 compiles and organizes the resistance gene sequences available in GenBanck, and the list of identifiable 115 sequences is available in the supplementary material Text S1. 116

2.4 Primer design

To design the primers, all variant sequences of each gene included in the study available on the 119 CARD platform were gathered, the sequences were aligned using the Clustal Omega software, and the alignments were analyzed using the SnapGene software. 121

Consensus regions with homology \geq 95% were selected and these were used to design the primers 122 using the Primer Blast platform from the National Center for Biotechnology and Information (NCBI, USA). 123 The consensus sequences obtained are available in the supplementary material Text S2. 124

Genes with few conserved regions, for which it was not possible to obtain consensus sequences with 125 homology \geq 95%, were separated into clades, and primers were then designed for the sequences by phylogenetic grouping, complying with a minimum of 95% similarity. 127

128

104

110

117

118

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

2.5 In silico validation of the developed primers

All primers developed were validated in silico regarding their specificity, structure, formation of primer-131 dimers and hairpins using the Primer-BLAST® (NCBI, USA) and Sequence Manipulation Suite (SMS): PCR 132 Primer Stats platforms.

2.6 Testing, optimization, and standardization of primers

The reactions were standardized with the use of positive controls developed in-house, through ampli-136 fication of genetic material, isolation, and purification of amplicons, originating from isolates phenotypically 137 resistant to beta-lactams, and negative control (water DNase/RNase free). They were carried out using a 138 CYBR Green master mix (Promega, Madison, USA), the initial results were evaluated regarding the melting 139 temperature (Tm), to confirm the specificity of the amplicons. 140

To determine the most efficient qPCR conditions, to reduce the existence of non-specificity and facil-141 itate the interpretation of the results, the concentration gradient and annealing temperature (Ta) of the primers 142 were performed. The gPCR reaction conditions included a hot start step at 95°C for 2 minutes, followed by 143 35 cycles consisting of a denaturation step for 15 seconds at 95°C, and an annealing/extension step for 1 144 minute at RT. specific to each primer, all reactions went through a final melting curve step, with a temperature 145 variation of 60 to 95°C with an increase of 0.05°C/sec. 146

A 9-point efficiency curve was performed with a dilution factor of 1:8, for each primer developed, with 147 concentrations ranging from \approx 27,438,596 to \approx 2 (copies/µL), through this procedure it was possible to de-148 termine the values of threshold, evaluate the efficiency (%), the correlation coefficient (R²) and the limit of 149 detection of each primer. 150

2.7 Detection of resistance-related genes by molecular biology

The K. pneumoniae isolates obtained in the study were tested against the developed primers. Melting 153 curve analysis of all reactions was used to evaluate the specificity of the results of the isolates in comparison 154 to the specific melting temperature (Tm) of the positive control. 155

2.8 Methodology for collecting susceptible and resistant Klebsiella pneumoniae samples.

Samples of K. pneumoniae susceptible and multidrug resistant to antimicrobial agents were collected 158 from patients hospitalized between April 23, 2019, and May 29, 2021, in the Intensive Care Unit of the Uni-159 versity Hospital, Faculty of Medicine, UFC, and they were submitted for metabolomic analysis. For this ex-160 periment, seven samples of the culture supernatant were designed: one sample of the culture medium, two 161 samples of the culture supernatant of susceptible K. pneumoniae (biological replicates), four samples of the 162 culture supernatant of multidrug-resistant K. pneumoniae (MDR) for untargeted metabolomics determination 163 and analysis. Samples of the intracellular medium of the K. pneumoniae culture, two samples of susceptible 164 K. pneumoniae (biological replicates) and four samples of MDR K. pneumoniae were also used for untargeted 165 metabolomic analysis. Technical replicates were performed for susceptible media and samples to allow for a 166 pilot statistical comparison. 167

2.9 Methodology for extracting K. pneumoniae culture supernatant.

To 200 µL of K. pneumoniae culture medium or control medium, 800 µL of 80% methanol was added 170 at -20 °C. The samples were vortexed and incubated at -20 °C for 2 hours for protein precipitation. The sam-171 ples were centrifuged for 10 min at 4°C at 10,000 g (Benchtop refrigerated centrifuge 10k RPM Eppendorf) 172 and the supernatants were transferred to new tubes. The samples were dried under vacuum (Speed Vac 173

133

130

134 135

151

152

156

157

168

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Thermo fisher) for approximately 4-5 hours. Dried samples were redissolved in 100 µL of 0.1% formic acid in 174 water containing Metabolomics QReSS labeled heavy standards diluted 100X. (https://www.iso-175 tope.com/userfiles/files/assetLibrary/MET_RSCH_QReSS.pdf). A quality control (QC) was done, combining 176 10 µL of each sample. After the QC test in the mass spectrometer, the samples were diluted 10x to be 177 analyzed. The injection volume of each sample was 10 µL per ionization mode. 178

2.10 Methodology for extractions from the intracellular medium of K. pneumoniae culture

To each tube, 750 µL of cold chloroform:methanol (2:1) mixture at -20 °C was added, vortexed and 181 transferred to tubes reinforced with a ball beater. Cells were disrupted in a bead beater with steel balls for 3 182 min at an intensity of 5 (Bead Ruptor Elite Omni International Material). The tubes were shaken vigorously 183 for 30 min at 4°C in a temperature-controlled thermal shaker (Thermomixer Eppendorf). 400 µL of water was 184added, shaken vigorously, and centrifuged for 10 min at 10,000 rpm (Benchtop refrigerated centrifuge 10k 185 RPM Eppendorf) for phase separation. The upper aqueous/methanolic phase was saved as a mixture of 186 soluble metabolites and transferred to Eppendorf tubes. Soluble metabolites were dried under vacuum for 3-187 4 h (Speed Vac Thermo Fisher). Before running, samples were reconstituted in 100 µL of 0.1% formic acid 188 in water containing 100X diluted Metabolomics QReSS labeled heavy standards (https://www.iso-189 tope.com/userfiles/files/assetLibrary/MET_RSCH_QReSS.pdf). The QC sample was prepared with 10 µL of 190 each sample. The injection volume of each sample was 10 µL. 191

2.11 Analysis by Ultra Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry (UPLC-MS/MS) of metabolites.

MS data were acquired on the Orbitrap IDX spectrometer (Thermo) connected to the Vanquish UPLC 195 system. Soluble metabolites were separated using a Waters BEH C18 column (100 x 2.1 mm, 1.9 µm) oper-196 ated at 30 °C and a flow rate of 250 µL/min. Mobile phase A was 0.1% formic acid in water and mobile phase 197 B was 0.1% formic acid in 90% methanol. Bulk scan range: 67-1000 at 120,000 resolutions with 0.6 sec scan 198 range. The 10 most intense ions in each full scan were selected for fragmentation and MS2 spectra were 199 acquired at a resolution of 30,000 and scaled collision dissociation fragmentation energy of 25, 30, 35 was 200 used. 201

2.12 UPLC gradient

The total time used in the UPLC gradient runs was 15 minutes. The flow used was 0.250 mL/min and 204 the following gradient in the percentage of mobile phase B was 50% at 8 min, 98% at 9 min. maintaining until 205 a time of 13 min., ending with 0% between a time of 13.1 – 15 min. 206

2.13 Verification settings in the mass spectrum

The configurations used in the verification through the mass spectrum were orbit trap of the mass spec-209 trum in the master scan, with an orbitrap detector with a resolution of 120,000. We used quadrupole isolation 210 with a scanning range between 67-1000 m/z, using the frequency lens at 60%. The automatic gain control 211 target was customized and normalized to 25%. The maximum injection time mode has been customized with 212 a maximum injection time of 50 ms. MIcroscans of 1 and profile with positive polarity. Font fragmentation has 213 been disabled. 214

215

179

180

192

193

194

202

203

207

- 216
- 217

perpetuity. It is made available under a CC-BY-ND 4.0 International license.

2.14 Data acquisition, metabolic identification, and data analysis. 218 Once the data was acquired, the samples were analyzed using the open-source software MS-DIAL. 219 More details about the software can be obtained here: http://prime.psc.riken.jp/compms/msdial/main.html 220 [15,16]. Three blank samples were included in the analysis to identify background ions and remove them 221 later. Samples acquired using MS1 full scan used for guantification and data-dependent acquisition (DDA) 222 mode were used for spectral identification of metabolites. Tolerance MS1 was set to 0.01 Da and MS2 set to 223 0.025 Da. For peak harvesting, the mass slice width was set to 0.1. For peak alignment, the maximum reten-224 tion time tolerance was set at 0.5 min, the MS1 tolerance was set at 0.01. Peaks were identified by searching 225 MS2 spectra in the public MS-DIAL database downloaded in January 2023 (324,191 records for positive 226 mode and 64,669 entries for negative mode) using a mass tolerance of 0.01 Da for MS1 and 0.05 Gives to 227 MSMS with an identification cutoff point of 80% http://prime.psc.riken.jp/compms/msdial/main.html#MSP. Ad-228 ditionally, peaks were also searched against the core Biomolecular Analysis Facility's internal IROA library 229 (both positive and negative mode) with a mass tolerance of 0.02 and identification cutoff of 85%. The data 230 was manually inspected and identifications without MS2 were filtered, except for identifications of the IROA 231 molecule. 232

3. Results

3.1. Selection of bacterial samples

A total of 249 samples of gram-negative bacteria resistant to beta-lactam antimicrobials, fluoroquin-235 olones, aminoglycosides, macrolides and glycopeptides were identified, among which the most prevalent 236 microorganism was Klebsiella pneumoniae 48.99% (122/249).

3.2. Identification of the phenotypic profile of beta-lactams resistance of K. pneumoniae strains

The bacteria isolates included in the study were tested against a wide range of beta-lactams drugs, 240 and the presence of a high percentage of isolates resistant to these drugs was verified, which included pen-241 icillins: ampicillin (100.00%), ampicillin/sulbactam (92.00%) and piperacillin/tazobactam (88.46%), cephalo-242 sporins: cefepime (83.02%), cefoxitin (73.68%), ceftazidime (86.54%), ceftazidime/avibactam (11.76%), 243 ceftriaxone (83.02%), cefuroxime (90.38%) and cefuroxime axetil (81.82%) and carbapenems: ertapenem 244 (44.00%), imipenem (71.70%) and meropenem (69.81%), as shown in Figure 1. 245

237

238

239

233



Figure 1. Prevalence of K. pneumoniae isolates resistant to the beta-lactams evaluated (Penicillins, Cephalo-246 sporins and Carbapenems), demonstrating a phenotypic profile of resistance to multiple beta-lactams drugs, in 247 more than 70% of the isolates, with the exception of ceftazidime/avibactam and ertapenem. 248

3.3. Primers design

After selection on the Comprehensive Antibiotic Resistance Data-base (CARD) platform and subse-251 quent compilation and analysis of FASTA sequences, it was possible to identify consensus sequences com-252 mon to all sequences available in the database (CARD) for each of the genes included in the study: blaSHV 253 (N = 156), *blaTEM* (N = 167), *blaNDM* (N = 27), *blaKPC* (N = 19), *blaGES* (N = 25), and *blaCTX-M* (N = 144). 254 Except for the *blaOXA* gene, for which the most clinically relevant sequences were used (N = 203). 255

The *blaCTX-M* and *blaOXA* genes, due to their diversity and high degree of genetic variation between 256 homologous sequences, were grouped into clades, and divided into CTX-M1 (N = 42), CTX-M2 (N = 16), 257 CTX-M 3 (N = 49), CTX-M 4 (N = 14) and CTX-M 5 (N = 23), while the blaOXA gene was divided into the 258 OXA-23 like groups (N = 25), OXA-24/40 like (N = 8), OXA-48 like (N = 17) and OXA-51 like (N = 153), as 259 can be seen in Figures 2 and 3. 260



Figure 2. Cladogram of the *blaOXA* subfamily showing the most epidemiologically relevant groups, covered by262the primers developed, and the percentage of sequences identifiable by each primer in comparison with the total263number of the *blaOXA* family (N = 441) at the time of publication of this work.264

261

265

266 267



Figure 3. Cladogram with all sequences from the *blaCTX-M* subfamily divided into groups, illustrating the identi-268fiable sequences, and the percentage of sequences detectable by each primer in comparison with the total num-269ber of the *blaCTX-M* family (N = 144) until the time of publication of this work.270

A total of 14 pairs of primers were developed, which together have the capacity to detect 740 variants of 271 resistance genes belonging to the *bla* gene family. The primer sequences for genes with conserved and non-272 conserved sequences can be found in **Tables 1** and **2**, respectively. 273

Table 1. Primer sequences for conserved genes						
Name of gene	Number of variations detectable	Name of primer	f Sequence	Size primer		
<i>bla</i> SHV	156	SHV-F	ATTATCTCCCTGTTAGCCACCC	22		
		SHV-R	GTTTAATTTGCTCAAGCGGCTG	22		
blaTEM	167	TEM-F	ACCCAGAAACGCTGGTGAAA	20		
		TEM-R	GGGGCGAAAACTCTCAAGGA	20		
<i>bla</i> NDM	27	NDM-F	GAAGCTGAGCACCGCATTAG	20		
		NDM-R	CCATTTGCTGGCCAATCGTC	20		
<i>bla</i> KPC	19	KPC-F	TCGCGGAACCATTCGCTAAA	20		
		KPC-R	GAATGAGCTGCACAGTGGGA	20		
<i>bla</i> GES	25	GES-F	GCCCAGGAGAGAGATTACGC	20		
		GES-R	CTTGACCGACAGAGGCAACT	20		

Table 2. Primer sequences for non-conserved genes, divided into clades.

Name of gene		Number of variations detectable	Name of primer	Sequence	Size primer
<i>bla</i> CTX-M	blaCTX-M 1	42	CTXM-F1	GATTGCGGAAAAGCACGTCA	20
			CTXM-R1	TTCATCGCCACGTTATCGCT	20
	blaCTX-M 2	16 -	CTXM-F2	CGCCGCTGATTCTGGTCA	18
			CTXM-R2	TGACGATTTTAGCCGCCGAC	20
	blaCTX-M 3	49	CTXM-F3	CGTGGCTCAAAGGCAATACG	20
			CTXM-R3	TCTGTTGCGGCTGGGTAAAA	20
	blaCTX-M 4	14 -	CTXM-F4	CGCTCAACACCGCGATCC	18
			CTXM-R4	ATCCCCGACAACCCACGAT	19
	blaCTX-M 5	23	CTXM-F5	ATGGCGCAGACCCTGAAAAA	20
			CTXM-R5	CTGCCGGTTTTATCGCCCA	19
blaOXA -	blaOXA-23like	24	OXA23L-F	GCTCTAAGCCGCGCAAATAC	20
			OXA23L-R	TGACCTTTTCTCGCCCTTCC	20
	blaOXA-24/40like	8 -	OXA24/40L-F	TGCCGATGACCTTGCACATA	20
			OXA24/40L-R	CCATTAGCTTGCTCCACCCA	20
	blaOXA-48like	17 -	OXA48L-F	CGGTAGCAAAGGAATGGCAAG	21
			OXA48L-R	GGGCGATCAAGCTATTGGGA	20
	blaOXA-51 like	153 -	OXA51L-F	GATCGGCCTTGAGCACCATA	20
			OXA51L-R	GCCATAACCAACACGCTTCA	20

3.4. Validation of primers

3.4.1. In silico validation

The parameters obtained for each primer after analysis using the Primer-BLAST® (NCBI, USA) and 281 Sequence Manipulation Suite (SMS): PCR Primer Stats software are available in Table 3. 282

Table 3. Parameters obtained by in silico validation of the developed primers.

				Self	Self 3'		
Gene	Nome do	Tm (C°)	GC%	complementa-	complementa-	Produt	
	primer			rity	rity	length	
	SHV-F	59,2	50,0	3	0	70	
DIASHV	SHV-R	59,3	45,4	5	3		
bloTEM	TEM-F	60,1	50,0	4	0	110	
	TEM-R	59,9	55,0	2	1	110	
<i>bla</i> NDM	NDM-F	59,3	55,0	5	1	96	
	NDM-R	60,1	55,0	6	2	80	
have	KPC-F	60,3	50,0	4	2	128	
blakPC	KPC-R	60,3	55,0	5	1		
	GES-F	59,9	60,0	3	2	94	
blaGES	GES-R	59,9	55,0	3	2		
blaCTV M 4	CTXM-F1	59,7	50,0	4	1	07	
	CTXM-R1	60,1	50,0	4	2	87	
HIGTY M O	CTXM-F2	60,1	61,1	3	2	90	
DIAC I X-IVI Z	CTXM-R2	61,0	55,0	3	3		
	CTXM-F3	59,9	55,0	3	2	400	
biacTX-M 3	CTXM-R3	60,1	50,0	3	0	180	
	CTXM-F4	61,5	66,6	4	2	107	
	CTXM-R4	60,9	57,8	3	2	197	
	CTXM-F5	60,5	50,0	4	0	165	
DIAC I X-IVI S	CTXM-R5	60,7	57,8	4	1	155	
	OXA23L-F	60,0	55,0	4	0	400	
DIAOAA-2311Ke	OXA23L-R	59,9	55,0	2	0	129	
	OXA24/40L-	50.7	50.0	4	2		
blaOXA-	F	59,7	50,0	4	2	177	
24/40 <i>like</i>	OXA24/40L-	60,0	55,0	4	0	177	
		50.9	52.2	2	0		
blaOXA-48 <i>like</i>		50.8	55.0	<u>ح</u>	0	183	
		50.9	55,0	4	0		
blaOXA-51 <i>like</i>		50 1	50.0	4 2	<u> </u>	199	
	OVADIT-R	59,1	50,0	2	I		

3.4.2. Testing, optimization, and standardization of *in vitro* reactions.

All primers were tested using positive controls developed in-house, and it was possible to verify that 286 the ideal annealing temperature (Ta) for the developed primer pairs was 61°C, except for the primer referring 287

284

285

279

280

to the *blaNDM* gene, for which the ideal Ta was 64°C. The reactions were then evaluated for their specificity 288 and stability by checking the Melting curve (Tm). The melting curves are available in the supplementary 289 material Figure S3. 290

291

292

3.4.3. Efficiency curve

It was found that all tested primers presented an efficiency rate \geq 93.21 and \leq 101.28%, R² \geq 0.99, 293 and detection limit between \approx 2 and \approx 13 copies/µL as shown in **Table 4**. 294

295

296

297

Table 4. Results of the efficiency curves of the developed primers.

Gene name	Efficiency (%)	Correlation coef- ficient (R ²)	Threshold	Detection li- mit (Copies/µL)	Melting Peak (Tm°C)
blaSHV	96,15	0,992	0,60	≈2	86,7
blaTEM	95,32	1,000	0,70	≈2	81,5
<i>bla</i> NDM	99,90	0,999	0,48	≈2	85,7
<i>bla</i> KPC	100,44	0,992	0,24	≈2	85,7
<i>bla</i> GES	100,21	0,997	0,27	≈2	81,7
<i>bla</i> CTX-M 1	95,75	0,999	0,40	≈13	84,3
blaCTX-M 2	100,82	0,994	0,32	≈13	83,2
blaCTX-M 3	97,82	0,996	0,10	≈2	89,0
blaCTX-M 4	95,32	1,000	0,10	≈13	88,4
blaCTX-M 5	98,09	0,998	0,30	≈2	86,4
blaOXA-23like	99,51	1,000	0,15	≈2	78,4
blaOXA-24/40like	101,82	0,988	0,15	≈13	78,7
blaOXA-48like	93,21	1,000	0,20	≈13	80,29
blaOXA-51 like	95,51	0,993	0,55	≈2	82,0

3.5. Identification of the genetic resistance profile of K. pneumoniae isolates

The 122 *K. pneumoniae* isolates were tested against the 14 pairs of primers developed, and it was possible to verify a high prevalence of beta-lactam resistance genes among the isolates analyzed. The most prevalent genes detected in the analyzed isolates were, respectively: *blaKPC* (95.90%); *blaSHV* (94.26%); *blaCTX-M* 2 (88.52%); *blaCTX-M* 5 (83.61%); *blaCTX-M* 1 (80.33%); *blaTEM* (80.33%); *blaNDM* (33.61%); *blaOXA-23like* (28.69%); *blaGES* (20.49%); *blaOXA-51like* (15.57%); *blaCTX-M* 3 (13.93%); *blaCTX-M* 4 (12.30%); *blaOXA-24/40like* (11.48%) and *blaOXA-48like* (3.28%). The results can be seen in **Figure 4**, grouped according to Ambler's *classification*.

Through the data obtained through the qPCR reactions developed, it was also possible to verify that 307 the isolates analyzed during this study had the presence of several genes belonging to the *bla* family accumulated, with values varying from 3 to 12 of the tested genes, present per isolate, as shown in **Figure 5**. 309

> Carbapenen blaOXA-48like Class D ases blaOXA-23like B (B1) Class D ESBI blaOXA-51like blaOXA-24/40like Class blaNDM Carbapenem Class A blaGES ases blaKPC blaCTX-M 4 blaCTX-M 3 bla TEM Class A ESBL blaCTX-M 1 blaCTX-M 5 blaCTX-M 2 bla SHV 0,00 20,00 40,00 60,00 80,00 100.00

Figure 4. Prevalence of beta-lactams resistance genes among the analyzed isolates, grouped according to the Ambler classification, where it is possible to verify the presence of a high detection rate for class A ESBL (*blaSHV*; *blaCTX-M* of clade 2, 5 and 1 respectively; *blaTEM*), marked presence of the carbapenemase *blaKPC*, and the metallo beta-lactamase NDM, in addition to the identification of *blaOXA-24/40like*, *blaOXA-51like* and *blaOXA-23like*, commonly associated with *Acinetobacter baumannii* strains.

315 316

311

312

313

314

299

310

perpetuity. It is made available under a CC-BY-ND 4.0 International license .



Figure 5. The percentage of K. pneumoniae isolates showing accumulation of genes encoding beta-lactamases belonging to the bla family. Where, it appears that among the 122 isolates evaluated, the majority of 22.13% present 6 of the genes evaluated in the study, demonstrating a high rate of sharing of these genes in the hospital environment.

3.6 Comparisons of metabolomic profiles between supernatants of susceptible or resistant K. pneumoniae versus the control culture media.

In total, 241 metabolites were identified in positive mode and 116 metabolites identified in negative 328 mode. Of these, 309 metabolites were identified by combining data from both acquisition modes (positive 329 and negative) without redundancy. 330



Comparison between susceptible K. pneumoniae supernatants (Sens) versus culture media

319 320

321

322

323

324 325

326

327

Figure 6 - Plots of the principal component analysis (PCAs) and the heatmap of the comparison of333metabolites between the supernatant of susceptible K. pneumoniae versus the control culture me-334dia. Observe the complete separation of the main vectors of the PCA plots and details of the differ-335ences in the heatmap between the two experimental groups.336

Figure 6 shows the results using principal component analysis (PCAs) plots and the heatmap of the 338 comparison of metabolites between the supernatant of sensitive K. pneumoniae versus the control culture 339 medium. Observe the complete separation of the main vectors of the PCA plots and details of the differences 340 in the heatmap between the two experimental groups. Figures S2, S3 and S4 show the analyzes of the 25 341 main metabolites analyzed, together and separated by up-regulated and down-regulated. Note that in the 342 supernatant of susceptible K. pneumonia compared to the culture medium, metabolites related to the syn-343 thesis of nitrogenous bases, protein synthesis and energy supply to the bacterial cell are significantly in-344 creased. 345



Figure 7 - Plots of the principal component analysis (PCAs) and the heatmap of the comparison of metabolites between the supernatant of *K. pneumoniae* MDR versus the control culture media. Note here also the complete separation of the main vectors of the PCA plots and details of the differences in the heatmap between the two experimental groups.

Figure 7 shows the results using principal component analysis (PCAs) plots and the heatmap for the 352 comparison of metabolites between the K. pneumoniae MDR supernatant versus the control culture medium. 353 Note here also the complete separation of the main vectors of the PCA plots and details of the differences in 354 the heatmap between the two experimental groups. Figures S5, S6 and S7 show the analyzes now using the 355 MDR *K. pneumoniae* strains compared to the control culture medium. Also note that in the supernatant of *K. 356 pneumoniae* MDR, metabolites related to the synthesis of nitrogenous bases, protein synthesis and energy 357 supply to the bacterial cell are significantly increased. 358

359

346

347

348

349

350 351

337

3.7 Comparisons of metabolomic profiles between supernatants or intracellular media of susceptible versus resistant K. pneumoniae





Figure 8 - Principal component analysis (PCAs) plots and heatmap of the supernatant of *K. pneu-moniae* susceptible and MDR. Observe the separation of the main vectors of the (PCAs) plots and details of the differences in the heatmap between the two experimental groups.

Figure 8 shows the PCAs and heatmap plots of supernatant from sensitive and MDR K. pneumoniae. 370



Figure 9 - Plots of dysregulated metabolites between supernatants of *K. pneumoniae* susceptible and MDR. Note that only one metabolite, N-fructosyl isoleucine, showed a significant increase (p < 0.05) in the MDR K. pneumoniae group.

In **Figure 9** we observe the analysis of deregulated metabolites between these experimental groups. ³⁷⁶ Note that only one metabolite, N-fructosyl isoleucine, showed a significant increase in the MDR K. pneumoniae group. Analysis of the intracellular media of susceptible versus MDR K. pneumoniae showed differences in the PCAs vectors, heatmap and that only the N-fructosyl metabolite isoleucine is significantly increased in the MDR K. pneumoniae group (**Figures 10** and **11**). ³⁷⁶



Figure 10 - Principal component analysis (PCAs) plots and heatmap of the intracellular environment of susceptible *K. pneumoniae* and MDR. Observe the separation of the main vectors of the (PCAs) plots and details of the differences in the heatmap between the two experimental groups.

Dysregulated metabolites of the intracellular media of *K. pneumoniae* multidrug-resistant (MDR) versus susceptible



Figure 11 -Plots of dysregulated metabolites between the intracellular media of susceptible*K. pneumoniae* and MDR. Note that only one metabolite, N-fructosyl isoleucine, showed a significant increase (p < 0.05) in the MDR K. pneumoniae group.</td>

390 391

387

388

389

381

382

383

384

385

386

4. Discussion

During the period analyzed in the study, 249 bacterial isolates resistant to one or more of one class 395 of antimicrobials used in TSA were identified. Of these resistant isolates, 48.99% (122/249) belonged to the 396 species Klebsiella pneumoniae, meaning that this microorganism was the most prevalent among those iden-397 tified. 398

This data is consistent with what is seen in Egypt, where when evaluating 186 samples from Cairo 399 hospitals, K. pneumoniae was found as the main gram-negative bacterial agent representing 40.9% (76/186) 400 of the identified microorganisms, and among these isolates obtained, a high prevalence of resistance to beta-401 lactams, guinolones, and sulfonamides was identified (89.4%, 89.4% and 87.1%) respectively [17]. The phe-402 notypic profile of the K. pneumoniae isolates analyzed in the present study demonstrated high levels of re-403 sistance to the beta-lactams drugs tested in all classes evaluated (penicillins, cephalosporins and car-404 bapenems). Although the resistance profile of strains may vary depending on the location and conditions to 405 prevent the spread of resistance, the presence of resistance to beta-lactams among Enterobacteriaceae is 406 reportedly high, as demonstrated in a study carried out in Brazil, with samples of human and veterinary origin 407 where 74.28%, 62.85% and 54.28% of Enterobacteriaceae isolated were resistant to ampicillin, amoxicil-408 lin/clavulonate and cefazolin respectively [18]. 409

In studies carried out in Egypt, evaluating isolates of K. pneumoniae from food sources, and in Tunisia 410 evaluating isolates from hospital samples, the presence of high resistance to beta-lactams can be verified for 411 ceftazidime (95.5%), cefoxitin (95.5%), cefotaxime (93.2%), amoxicillin/clavulonate (86.4%), ertapenem 412 (90.9%) and temocillin (84.0%) [19, 20]. 413

Likewise, in a study carried out with 102 isolates obtained from two Portuguese hospitals, the pres-414 ence of resistance rates > 90% was verified for all beta-lactam drugs tested, except for cephalosporins: 415 cefoxitin (40.2%), cefotetan (68.6%) and carbapenems: ertapenem (23.5%), imipenem (32.4%), meropenem 416 (34.3%) and doripenem (33.3%) [21]. 417

This result is consistent with that found in this study, where the beta-lactam drugs that showed a lower 418 resistance rate belonged to the same classes mentioned, namely: cefoxitin (73.68%), ceftazidime/avibactam 419 (11.76%), ertapenem (44.00%), imipenem (71.70%) and meropenem (69.81%). 420

Resistance to beta-lactams is conferred in gram negatives mainly by genes belonging to the *bla* family. 421 This group of genes is composed of dozens of subfamilies and hundreds of genetic subvariants in each family, 422 the molecular panel developed managed to encompass the most predominant subfamilies and clinically rel-423 evant among clinical isolates, identified in several studies, namely: blaSHV, blaTEM, blaNDM, blaKPC, 424 blaGES, blaCTX-M and blaOXA [22, 23, 24]. After analysis using the Primer-BLAST® (NCBI, USA) and 425 Primer Stats Sequence Manipulation Suite (SMS) software, it was verified that the developed primers have 426 specificity for the sequences used in the alignment, melting temperature (Tm) between 59 29° C and 61.55° 427 C, GC% concentration varying between 45.45% and 66.67% in addition to having complementary base num-428 bers \leq 6 in the analysis of dimer and hairpin formation. The values obtained for these parameters therefore 429 demonstrate that they are compatible with those obtained in reference studies [25, 26, 27]. 430

Due to the high number of sequences included in the development of primers, many of the alternatives 431 obtained through Primer-BLAST® (NCBI, USA) did not meet the stability requirements regarding the for-432 mation of secondary structures (self-annealing and hairpins), In order to choose the options with the best 433 performance in relation to these parameters, the GC clamp was relaxed so that the primers SHV-F, SHV-R, 434 CTXM-R2 and CTXM-R5 obtained 4 G or C residues within the last 5 nucleotides of the 3' end, the primers 435 CTXM-R3 and CTXM-F5 did not present C or G residues within the last 5 nucleotides of the sequence. 436

This fact could lead to the formation of strong bonds and increase the Tm value in primers with more 437 than 3 terminal GC residues, and cause inhibition of amplification due to the presence of weak bonds when 438 there is an absence of terminal CG [26, 27]. Such changes, however, were not evident when the primers 439 were tested in vitro. 440

The variety of sequences detectable by the developed primers makes in vitro validation using positive 441 controls for all sequences virtually impossible. In silico analysis allowed the evaluation of all tested sequences 442 guickly, cheaply, and constantly, since the developed primers can be tested against new variants of the target 443 genes [26, 28]. 444

In vitro analyzes were carried out using SYBR Green master mix, the melting curve was therefore 445 used as a parameter to evaluate the specificity of the reactions. And it was verified that for all tested primers 446 a single melting peak was found, indicating the formation of a single amplicon. And excluding the presence 447 of secondary structures (primer dimers and hairpins). 448

The analysis of the melting curve and Tm is considered fundamental to test the specificity of reactions 449 that use CYBR Green as an amplification indicator, because unlike reactions that use specific probes, which 450 emit fluorescence only when the reaction occurs at the expected target. The CYBR Green works by binding 451 to any double-stranded fragment formed, thus emitting fluorescence. Therefore, only by analyzing the melting 452 curve and the specific Tm of the amplicon is it possible to determine whether the reaction was successful [29, 453 30, 31]. 454

The efficiency curve and its parameters were used to evaluate the performance of qPCR reactions, 455 by checking how efficiently the targets were amplified in each PCR cycle [32, 33]. When evaluating the activity 456 of primers in qPCR reactions using the efficiency curve, it was found that all primers analyzed in this study 457 presented efficiency values >90% and <110% and correlation coefficients (R²) >0.9, thus being in accordance 458 with the parameters presented in reference documents present in the literature [33]. It was also possible to 459 verify a high detection capacity even at low concentrations of genetic material since the detection limit ob-460 tained varied between ≈ 2 and ≈ 13 copies/µL of the target gene used as control. 461

Several studies report the growth in the prevalence of the *blaKPC* gene, with carbapenemase being 462 the most detected worldwide. The values found vary according to the location. The main variant of the blaKPC 463 gene detected is *blaKPC-2*, with prevalence values varying from 1.2% to 51.6% among enterobacteria in 464 studies carried out in the United States of America and China respectively [34, 35]. This gene is found more 465 frequently in isolates of K. pneumoniae, studies report high prevalence rates in this species ranging from 466 17.2% to 64.6% [34, 36, 37, 38]. 467

The higher values found in this study for the *blaKPC* gene may be the result of both the fact that the 468 primer developed detected all variants of the gene, as well as the fact that the samples from which the isolates 469 were obtained came from an intensive care unit (ICU), where It is known that infection and colonization rates 470 by resistant microorganisms are higher, due to the high exposure of microorganisms to antimicrobials such 471 as carbapenems and fluoroquinolones [39]. 472

The blaTEM and blaSHV genes were the first ESBL identified, and together with the blaCTX-M sub-473 family of genes, they are considered the most prevalent ESBL. These genes are widely distributed among 474 enterobacteria; in a study carried out in Sudan, the blaTEM, blaCTX-M and blaSHV genes were identified in 475 86.0%, 78.0% and 28.0% respectively [40]. 476

In work carried out in ICUs in Chile, it was possible to verify the presence of these genes with preva-477 lence rates of 81.0%, 84.7% and 73.0% for blaSHV, blaCTX-M-1 and blaTEM, where a higher prevalence of 478 the blaSHV gene compared to the study carried out in Sudan. These results agree with those evidenced in 479 this study for the K. pneumoniae isolates tested [41]. 480

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

The *blaNDM* gene is considered the second most prevalent carbapene-mase producing gene in the world, behind only the *blaKPC* gene. In this study, the presence of the metallo beta-lactamase NDM was verified in (33.61%) of the isolates. Similar results were evidenced in China, where the presence of this gene was verified in 35.7% of 935 carbapenem-resistant enterobacteria tested [34].

Regarding oxacillinases, a low prevalence of the *blaOXA-48like* gene was observed (3.28%). This 485 gene may be present in all *Enterobacteriaceae*; however, it is more prevalent in strains of *K. pneumoniae* 486 [22].

The values found in the literature for the presence of this gene in *Enterobacteriaceae* are very divergent, with marked variations related to the location of the analysis, these values vary from 7.3% in China to 83.3% in Morocco [34, 42]. In a study conducted in Brazil where 4,451 isolates of *Enterobacteriaceae* were analyzed, the *blaOXA-48like* gene was detected in only 2.5% of the isolates tested [43]. In this way, the result obtained is compatible with what was previously identified in Brazil, and close to what is seen in China.

The presence of variants of the *blaOXA* gene (*bla-OXA-51like* (15.57%), *blaOXA-24/40like* (11.48%) 493 and *blaOXA-23like* (28.69%)) was also observed in the isolates tested, these genes were long considered 494 exclusive to strains of *Acinetobacter baumannii*, however studies have demonstrated the presence of these 495 genes in other *Enterobacteriales*, including *K. pneumoniae* [44]. Results regarding the prevalence of these 496 genes in strains of *K. pneumoniae* are still scarce, however, in a study conducted in Bahrain in the Persian 497 Gulf, the *blaOXA-51* and *blaOXA-23* genes were identified respectively in 45.8% and 41.6%. % of *K. pneumoniae* 498 *moniae* isolates analyzed [45].

It is believed that many of the beta-lactamases that today can be found contained in mobile genetic ⁵⁰⁰ elements had their origin in chromosomes of other bacteria, as occurred with the *SHV* type variants that ⁵⁰¹ derived from the *K. pneumoniae* chromosomal *SHV-1*, and the *CTX-M* type variants that appear to have ⁵⁰² originated from the chromosomal CTX-m of *Kluyvera* spp. [22]. This change in the presentation of these ⁵⁰³ genes, from chromosomal to mobile elements, may explain the appearance of genes such as chromosomal ⁵⁰⁴ *blaOXA* present in *A. baumannii* strains on plasmids widespread in other species. ⁵⁰⁵

It was possible to verify the presence of isolates presenting multiple genes coding for beta-lactamases, 506 from 3 to 12 of the genes analyzed. Studies point to a high prevalence among *Enterobacteriaceae* of the 507 accumulation of genes from the *bla* family, mainly genes belonging to ESBL, *OXA* beta-lactamases and 508 carbapenemases such as *blaKPC* and *blaNDM*. This phenomenon is more evident in hospital environments 509 where selective pressure favors microorganisms carrying resistance genes and where there is a high rate of 510 sharing of these genes [46, 47].

Investigations into metabolomic modulation in K. pneumoniae have demonstrated a promising area 512 for understanding resistance to antimicrobial agents, developing new therapies, and for studying bacterial 513 virulence. For example, significant inhibition of the pentose phosphate pathway, citrate cycle, amino acid and 514 nucleotide metabolism was observed to be beneficial during treatment of MDR K. pneumoniae using the 515 bacteriophage-polymyxin combination, showing the potential for new therapeutic targets and pathways met-516 abolic processes to improve the effectiveness of treatment with available antimicrobial agents [48, 49]. In this 517 study, we highlighted the importance of the pentose phosphate pathway in MDR K. pneumoniae strains, in 518 both isolates from supernatants and intracellular media, compared with K. pneumoniae strains susceptible 519 to antimicrobial agents. The significant presence of the metabolic N-fructosyl isoleucine (C₁₂H₂₃NO₇; MW: 520 293.316) in the supernatant and intracellular media of K. pneumoniae MDR indicates the expression of the 521 fructose degradation enzyme gene (frwC; fructose-specific phosphotransferase system), which is involved in 522 regulating bacterial growth, virulence and overcoming colonization resistance due to the use of alternative 523 carbon source from fructose [50, 51]. 524

This study has some limitations, such as the exploration of only *bla* family genes, limiting a broader 525 understanding of resistance mechanisms to antimicrobial agents. On the other hand, it presents a broad 526 methodology for exploring the important *bla* family genes most associated with resistance to beta-lactams in 527 *K. pneumonia*. The metabolic findings showed a specific indication that suggests an association with virulence and better proteomic studies will be necessary to associate with potential mechanisms of resistance to 529 antimicrobial agents. Furthermore, additional preclinical studies will be necessary to determine and more specifically validate the virulence associated with the pentose phosphate pathway in *K. pneumoniae*. 531

5. Conclusions

The results of this work show the high prevalence of resistance to antimicrobial agents in strains of *K*. 534 *pneumoniae* within the hospital environment, and that this phenotypic pattern exhibited a great concern as it 535 limits the therapeutic options available, directly implicating the patient's prognosis. 536

The assays developed were within the quality criteria for qPCR reactions using SYBR Green master mix and were efficient in detecting the beta-lactams resistance *bla* family genes evaluated in this study. The genotypes of the *bla* genes obtained are relevant and worrying for the local hospital scenario, and compatible with the identified phenotypic profile. 540

The identification of the metabolic N-fructosyl isoleucine in the supernatant and intracellular media of 541 *K. pneumoniae* MDR indicates the expression of the fructose degradation enzyme gene, which is involved in 542 regulating bacterial growth, virulence and overcoming resistance to colonization due to the use of an alternative carbon source from fructose. 543

Figure supplement legend

 Figure S1 – Primer's specificity evaluation through Melting curve: (A) SHV, (B) KPC, (C) NDM, (D)
 547

 TEM, (E) GES, (F) OXA-23, (G) OXA-24/40, (H) OXA-48, (I) OXA-51, (J) CTX-M 1, (K) CTX-M 2, (L) CTX-M
 548

 3, (M) CTX-M 4 e (N) CTX-M 5
 549

Figure S2 - Plot analysis of the 25 main metabolites from the supernatant of susceptible K. pneumoniae in general without separation by up- or down-regulation of the analytes. Note that in the supernatant of K. pneumoniae compared to the culture media, metabolites related to the synthesis of nitrogenous bases, protein synthesis and energy supply to the bacterial cell are significantly increased. 553

Figure S3 - Plot of the analysis of the 25 main metabolites from the supernatant of susceptible K. 554 pneumoniae, separated because they were up-regulated in relation to the control culture media. 555

Figure S4 - Plot of the analysis of the 25 main metabolites from the supernatant of susceptible K. 556 pneumoniae, separated because they were down regulated in relation to the control culture media. 557

Figure S5 - Plot of the analyzes of the 25 main metabolites from the supernatant of multidrug resistant 558 (MDR) K. pneumoniae in general without separation by up- or down-regulation in the analytes. Note that in 559 the intracellular media of K. pneumoniae compared to the culture medium, metabolites related to the synthesis of nitrogenous bases, protein synthesis and energy supply to the bacterial cell are significantly increased. 561

Figure S6 - Plot of the analysis of the 25 main metabolites from the supernatant of K. pneumoniae562MDR, separated by being up-regulated in relation to the control culture media.563

Figure S7 - Plot d of the analysis of the 25 main metabolites from the supernatant of K. pneumoniae564MDR, separated because they were down-regulated in relation to the control culture media.565

566

532

533

545

546

Author Contributions:

Bibliographic review and data collection, Lavouisier F.B. Nogueira, Marília S. Maia, Marco A.F. Clementino and Aldo A.M. Lima; Methodology, Lavoui-sier F.B. Nogueira, Marília S. Maia, Marco A.F Clem-entino, Alexandre Havt, Ila F.N. Lima, Jorge L.N. Rodrigues, Luciana V. C. Fragoso and Aldo A. M. Lima; Bioinformatics, Lavouisier F.B. Nogueira and Marco A.F Clementino; In silico analyses, Lavouisier F.B. Nogueira, Marco A.F Clementino; In vitro validation of primers and sample testing, Lavouisier F.B. Noqueira, Marília S. Maia; Metabolomics, Datascience and data Bank, Jose Q.S. Filho; Deiziane V.S. Costa, José K. Sousa, Lyvia M.V.C. Magalhães, Dilza Silva, Nicholas E. Sherman and Aldo A.M. Lima; Writ-ten review and editing, Lavouisier F.B. Nogueira; Aldo A.M. Lima; Supervision, Alexandre Havt and Aldo A.M. Lima; Project administration, Aldo A.M. Lima; Resource acquisition, Aldo A.M. Lima.

Funding: This research was funded by CNPq (http://www.cnpq.br), grant numbers 402607/2018-0 and 580 408549/2022-0 and FUNCAP (https://www.funcap.ce.gov.br/), grant number: OFÍCIO Nº 102/2021 – DINOV. 581

Data Availability Statement: The data and reports relating to this study will be available via direct request via email to the corresponding author. 583

Conflicts of Interest: The authors declare that there are no financial or personal conflicts of interest that 586 may have influenced the work. 587

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

References

- 1. Munita, J.M.; Arias, C.A. Mechanisms of Antibiotic Resistance. *Microbiology Spectrum***2016**, *4*, 618 doi:10.1128/microbiolspec.vmbf-0016-2015. 619
- Frieri, M.; Kumar, K.; Boutin, A. Antibiotic Resistance. Journal of Infection and Public Health2017, 10, 620 369–378, doi:10.1016/j.jiph.2016.08.007.
- Holt, K.E.; Wertheim, H.; Zadoks, R.N.; Baker, S.; Whitehouse, C.A.; Dance, D.; Jenney, A.; Connor, T.R.; Hsu, L.Y.; Severin, J.; et al. Genomic Analysis of Diversity, Population Structure, Virulence, and Antimicrobial Resistance in *Klebsiella Pneumoniae*, an Urgent Threat to Public Health. *Proceedings of the National Academy of Sciences***2015**, *112*, doi:10.1073/pnas.1501049112.
- Mohd Asri, N.A.; Ahmad, S.; Mohamud, R.; Mohd Hanafi, N.; Mohd Zaidi, N.F.; Irekeola, A.A.; Shueb, R.H.; Yee, L.C.; Mohd Noor, N.; Mustafa, F.H.; et al. Global Prevalence of Nosocomial Multidrug-Resistant *Klebsiella Pneumoniae*: A Systematic Review and Meta-Analysis. *Antibiotics*2021, 10, 1508, doi:10.3390/antibiotics10121508.
- Sharma, A.; Thakur, A.; Thakur, N.; Kumar, V.; Chauhan, A.; Bhardwaj, N. Changing Trend in the Antibiotic Resistance Pattern of *Klebsiella Pneumonia* Isolated From Endotracheal Aspirate Samples of ICU
 Patients of a Tertiary Care Hospital in North India. *Cureus*2023, doi:10.7759/cureus.36317.
- Cortés, G.; Borrell, N.; de Astorza, B.; Gómez, C.; Sauleda, J.; Albertí, S. Molecular Analysis of the Contribution of the Capsular Polysaccharide and the Lipopolysaccharide O Side Chain to the Virulence of Klebsiella Pneumoniae in a Murine Model of Pneumonia. *Infection and Immunity***2002**, *70*, 2583–2590, doi:10.1128/iai.70.5.2583-2590.2002.
- Struve, C.; Bojer, M.; Krogfelt, K.A. Identification of a Conserved Chromosomal Region Encoding Klebsiella Pneumoniae Type 1 and Type 3 Fimbriae and Assessment of the Role 638 of Fimbriae in Pathogenicity. *Infection and Immunity*2009, 77, 5016–5024, doi:10.1128/iai.00585-09. 639
- Lin, C.-T.; Chen, Y.-C.; Jinn, T.-R.; Wu, C.-C.; Hong, Y.-M.; Wu, W.-H. Role of the cAMP-Dependent 640 Carbon Catabolite Repression in Capsular Polysaccharide Biosynthesis in Klebsiella Pneumoniae. 641 *PLoS ONE*2013, *8*, e54430, doi:10.1371/journal.pone.0054430. 642
- 9. Davies, J.; Davies, D. Origins and Evolution of Antibiotic Resistance. *Microbiology and Molecular Biology Reviews***2010**, *74*, 417–433, doi:10.1128/mmbr.00016-10. 643
- 10. Salipante, S.J.; Jerome, K.R. Digital PCR—An Emerging Technology with Broad Applications in Microbiology. *Clinical Chemistry***2019**, *66*, 117–123, doi:10.1373/clinchem.2019.304048.
- Bush, K.; Bradford, P.A. β-Lactams and β-Lactamase Inhibitors: An Overview. Cold Spring Harbor Perspectives in Medicine**2016**, 6, a025247, doi:10.1101/cshperspect.a025247.
- Ferreira, A.M.; Martins, K.B.; Silva, V.R. da; Mondelli, A.L.; Cunha, M. de L.R. de S. da Correlation of Phenotypic Tests with the Presence of the blaZ Gene for Detection of Beta-Lactamase. *Brazilian Journal* of *Microbiology***2017**, *48*, 159–166, doi:10.1016/j.bjm.2016.10.011.
- Zhu, L.-J.; Pan, Y.; Gao, C.-Y.; & Hou, P.-F. (2020). Distribution of Carbapenemases and Efflux Pump in Carbapenem-resistance Acinetobacter baumannii. *Annals of Clinical and Laboratory Science* 2020, 50(2), 241–246.
- 14. Agência Nacional de Vigilância Sanitária (ANVISA). Procedimentos Laboratoriais: da Requisição do 655 Exame à Análise Microbiológica e Laudo Final. 2. ed. Brasil: **2013**. Módulo 4. 656
- Tsugawa, H.; Cajka, T.; Kind, T.; Ma, Y.; Higgins, B.; Ikeda, K.; Kanazawa, M.; VanderGheynst, J.;
 Fiehn, O.; Arita, M. MS-DIAL: Data-Independent MS/MS Deconvolution for Comprehensive Metabo lome Analysis. *Nature Methods*2015, *12*, 523–526, doi:10.1038/nmeth.3393.
- Tsugawa, H.; Nakabayashi, R.; Mori, T.; Yamada, Y.; Takahashi, M.; Rai, A.; Sugiyama, R.; Yamamoto,
 H.; Nakaya, T.; Yamazaki, M.; et al. A Cheminformatics Approach to Characterize Metabolomes in Sta ble-Isotope-Labeled Organisms. *Nature Methods*2019, *16*, 295–298, doi:10.1038/s41592-019-0358-2.
- Makharita, R.R.; El-kholy, I.; Hetta, H.F.; Abdelaziz, M.; Hagagy, F.; Ahmed, A.; Algammal, A.M.
 <P>Antibiogram and Genetic Characterization of Carbapenem-Resistant Gram-Negative Pathogens Incriminated in Healthcare-Associated Infections</P> *Infection and Drug Resistance*2020, *Volume 13*, 3991–4002, doi:10.2147/idr.s276975.

616 617

645

 Santos, A.L.; dos Santos, A.P.; Ito, C.R.M.; Queiroz, P.H.P. de; de Almeida, J.A.; de Carvalho Júnior, M.A.B.; de Oliveira, C.Z.; Avelino, M.A.G.; Wastowski, I.J.; Gomes, G.P.L.A.; et al. Profile of Enterobacteria Resistant to Beta-Lactams. *Antibiotics*2020, *9*, 410, doi:10.3390/antibiotics9070410.

670

671

688

- 19. Abdel-Rhman, S.H. Characterization of β-Lactam Resistance in *K. Pneumoniae* Associated with Readyto-Eat Processed Meat in Egypt. *PLOS ONE***2020**, *15*, e0238747, doi:10.1371/journal.pone.0238747.
- Messaoudi, A.; Mansour, W.; Jaidane, N.; Chaouch, C.; Boujaâfar, N.; Bouallègue, O. Epidemiology of Resistance and Phenotypic Characterization of Carbapenem Resistance Mechanisms in *Klebsiella Pneumoniae* Isolates at Sahloul University Hospital-Sousse, Tunisia. *African Health Sciences***2019**, *19*, 2008, doi:10.4314/ahs.v19i2.24.
- Oliveira, R.; Castro, J.; Silva, S.; Oliveira, H.; Saavedra, M.J.; Azevedo, N.F.; Almeida, C. Exploring the Antibiotic Resistance Profile of Clinical *Klebsiella Pneumoniae* Isolates in Portugal. *Antibiotics*2022, *11*, 1613, doi:10.3390/antibiotics11111613.
- Bush, K.; Bradford, P.A. Epidemiology of β-Lactamase-Producing Pathogens. *Clinical Microbiology Reviews*2020, 33, doi:10.1128/cmr.00047-19.
- Castanheira, M.; Simner, P.J.; Bradford, P.A. Extended-Spectrum β-Lactamases: An Update on Their Characteristics, Epidemiology and Detection. *JAC-Antimicrobial Resistance*2021, 3, doi:10.1093/jacamr/dlab092.
- Gundran, R.S.; Cardenio, P.A.; Villanueva, M.A.; Sison, F.B.; Benigno, C.C.; Kreausukon, K.; Pichpol,
 D.; Punyapornwithaya, V. Prevalence and Distribution of blaCTX-M, blaSHV, blaTEM Genes in Ex tended- Spectrum β- Lactamase- Producing E. Coli Isolates from Broiler Farms in the Philippines. BMC
 Veterinary Research2019, 15, doi:10.1186/s12917-019-1975-9.
- Queiroz J.A.S.; Alves L.S.; Dall'acqua D.S.V.; Sousa L.F.B. Desenho e Validação de Primers In Silico para Detecção do Vírus Sincicial Respiratório Humano. *Revista FIMCA*2017, 4(1), 17-30.
- Kumar, A.; Chordia, N. In Silico PCR Primer Designing and Validation. In *Methods in Molecular Biology*, 690 Springer New York: New York, NY**2015**; pp. 143–151.
- Rodríguez, A.; Rodríguez, M.; Córdoba, J.J.; Andrade, M.J. Design of Primers and Probes for Quantitative Real-Time PCR Methods. In *Methods in Molecular Biology*; Springer New York: New York, 693 NY**2015**; pp. 31–56.
- van Weezep, E.; Kooi, E.A.; van Rijn, P.A. PCR Diagnostics: In Silico Validation by an Automated Tool Using Freely Available Software Programs. *Journal of Virological Methods*2019, 270, 106–112, 696 doi:10.1016/j.jviromet.2019.05.002.
- Yang, J.; Kemps-Mols, B.; Spruyt-Gerritse, M.; Anholts, J.; Claas, F.; Eikmans, M. The Source of SYBR
 Green Master Mix Determines Outcome of Nucleic Acid Amplification Reactions. *BMC Research Notes*2016, 9, doi:10.1186/s13104-016-2093-4.
- Wang, Y.; Li, W.; Guo, X.; Zhang, D.; Sun, J.; Fu, Z.; Liu, G.; Li, Y.; Jiang, S. Development of SYBR Green I-Based Polymerase Chain Reaction for Feline Bocavirus 1 Detection. *3 Biotech*2021, *11*, doi:10.1007/s13205-020-02577-8.
- Desriani; Azamris; Ghaissani, S.S.; Kinanti, S.R.; Warisman, M.A.; Fitria, N. Design and Characterization of a SYBR Green I-Based Melting Curve Method for Investigation of HER2I655V Polymorphism in Breast Cancer. *Journal of Genetic Engineering and Biotechnology***2021**, *19*, doi:10.1186/s43141-020-00108-9.
- Svec, D.; Tichopad, A.; Novosadova, V.; Pfaffl, M.W.; Kubista, M. How Good Is a PCR Efficiency Estimate: Recommendations for Precise and Robust qPCR Efficiency Assessments. *Biomolecular Detection and Quantification***2015**, *3*, 9–16, doi:10.1016/j.bdq.2015.01.005.
- Thermo Fisher Scientific. Real-time PCR: understanding Ct. Available online: https://www.thermofisher.com/content/dam/LifeTech/global/Forms/PDF/real-time-pcr-handbook.pdf. (accessed on 712 03/12/2023).
- Han, R.; Shi, Q.; Wu, S.; Yin, D.; Peng, M.; Dong, D.; Zheng, Y.; Guo, Y.; Zhang, R.; Hu, F. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China. *Frontiers in Cellular and Infection Microbiology***2020**, *10*, doi:10.3389/fcimb.2020.00314.
- Marschall, J.; Tibbetts, R.J.; Dunne, W.M., Jr.; Frye, J.G.; Fraser, V.J.; Warren, D.K. Presence of the KPC Carbapenemase Gene in Enterobacteriaceae Causing Bacteremia and Its Correlation with In Vitro Carbapenem Susceptibility. *Journal of Clinical Microbiology***2009**, *47*, 239–241, doi:10.1128/jcm.02123-08.

- Kharazmkia, A.; Amirizadeh, M.; Goudarzi, Z.; Birjandi, M.; Barfipoursalar, A.; Mir, S. Prevalence of KPC-Producing Bacteria in Negative Gram of Clinical Samples Obtained from Patients. *Annals of Medicine & amp; Surgery***2022**, 77, doi:10.1016/j.amsu.2022.103690.
- Pawłowska, I.; Ziółkowski, G.; Jachowicz-Matczak, E.; Stasiowski, M.; Gajda, M.; Wójkowska-Mach, J.
 Colonization and Healthcare-Associated Infection of Carbapenem-Resistant Enterobacteriaceae, Data
 from Polish Hospital with High Incidence of Carbapenem-Resistant Enterobacteriaceae, Does Active
 Target Screening Matter? *Microorganisms*2023, *11*, 437, doi:10.3390/microorganisms11020437.
- Mohd Asri, N.A.; Ahmad, S.; Mohamud, R.; Mohd Hanafi, N.; Mohd Zaidi, N.F.; Irekeola, A.A.; Shueb, R.H.; Yee, L.C.; Mohd Noor, N.; Mustafa, F.H.; et al. Global Prevalence of Nosocomial Multidrug-Resistant *Klebsiella Pneumoniae*: A Systematic Review and Meta-Analysis. *Antibiotics*2021, 10, 1508, doi:10.3390/antibiotics10121508.
- Kernéis, S.; Lucet, J.C.; Santoro, A.; Meschiari, M. Individual and Collective Impact of *Klebsiella Pneumoniae* Carbapenemase (KPC)-Producing *K. Pneumoniae* in Patients Admitted to the ICU. *Journal of Antimicrobial Chemotherapy***2021**, *76*, i19–i26, doi:10.1093/jac/dkaa494.
- Dirar, M.H.; Bilal, N.E.; Ibrahim, M.E.; Hamid, M.E. Prevalence of Extended-Spectrum β-Lactamase (ESBL) and Molecular Detection of Bla TEM, Bla SHV and Bla CTX-M Genotypes among Enterobacte-riaceae Isolates from Patients in Khartoum, Sudan. *Pan African Medical Journal***2020**, 37, doi:10.11604/pamj.2020.37.213.24988.
- Pavez, M.; Troncoso, C.; Osses, I.; Salazar, R.; Illesca, V.; Reydet, P.; Rodríguez, C.; Chahin, C.; Concha, C.; Barrientos, L. High Prevalence of CTX-M-1 Group in ESBL-Producing Enterobacteriaceae Infection in Intensive Care Units in Southern Chile. *The Brazilian Journal of Infectious Diseases*2019, 23, 102–110, doi:10.1016/j.bjid.2019.03.002.
- Belouad, E.M.; Benaissa, E.; El Mrimar, N.; Bssaibis, F.; Maleb, A.; Elouennass, M. Predominance of OXA-48 Carbapenemase-Producing Enterobacterales in a Moroccan Hospital. *International Journal of Microbiology***2023**, 2023, 1–10, doi:10.1155/2023/8581883.
- Magagnin, C.M.; Rozales, F.P.; Antochevis, L.; Nunes, L.S.; Martins, A.S.; Barth, A.L.; Sampaio, J.M.; Zavascki, A.P. Dissemination of Bla OXA-370 Gene among Several Enterobacteriaceae Species in Brazil. *European Journal of Clinical Microbiology & amp; Infectious Diseases*2017, 36, 1907–1910, doi:10.1007/s10096-017-3012-x.
- Evans, B.A.; Amyes, S.G.B. OXA β-Lactamases. Clinical Microbiology Reviews2014, 27, 241–263, doi:10.1128/cmr.00117-13.
- 45. Shahid, M.; Ahmad, N.; Saeed, N.K.; Shadab, M.; Joji, R.M.; Al-Mahmeed, A.; Bindayna, K.M.; Tabbara, 753 K.S.; Dar, F.K. Clinical Carbapenem-Resistant *Klebsiella Pneumoniae* Isolates Simultaneously Harbor-754 ing blaNDM-1, blaOXA Types and qnrS Genes from the Kingdom of Bahrain: Resistance Profile and 755 Genetic Environment. Frontiers in Cellular and Infection Microbiology2022, 756 doi:10.3389/fcimb.2022.1033305. 757
- Manandhar, S.; Zellweger, R.M.; Maharjan, N.; Dongol, S.; Prajapati, K.G.; Thwaites, G.; Basnyat, B.; Dixit, S.M.; Baker, S.; Karkey, A. A High Prevalence of Multi-Drug Resistant Gram-Negative Bacilli in a Nepali Tertiary Care Hospital and Associated Widespread Distribution of Extended-Spectrum Beta-Lactamase (ESBL) and Carbapenemase-Encoding Genes. Annals of Clinical Microbiology and Antimicrobials2020, 19, doi:10.1186/s12941-020-00390-y.
- Awosile, B.B.; Agbaje, M.; Adebowale, O.; Kehinde, O.; Omoshaba, E. Beta-Lactamase Resistance 763 Genes in Enterobacteriaceae from Nigeria. African Journal of Laboratory Medicine2022, 11, 764 doi:10.4102/ajlm.v11i1.1371.
- 48. Han, M.-L.; Nang, S.C.; Lin, Y.-W.; Zhu, Y.; Yu, H.H.; Wickremasinghe, H.; Barlow, C.K.; Creek, D.J.; 766 Crawford, S.; Rao, G.; et al. Comparative Metabolomics Revealed Key Pathways Associated with the 767 Synergistic Killing of Multidrug-Resistant Klebsiella Pneumoniae by a Bacteriophage-Polymyxin Com-768 bination. Computational and Structural Biotechnology Journal2022, 20. 485-495. 769 doi:10.1016/j.csbj.2021.12.039. 770
- Kumar, A.; Singh, S.; Gupta, S.K.; Kumar, S.; Kumar, S.; Singh, R.; Thakur, L.; Kumar, M.; Kapil, A.; 771
 Kumar, Y.; et al. Identification of Metabolite Extraction Method for Targeted Exploration of Antimicrobial 772
 Resistance Associated Metabolites of Klebsiella Pneumoniae. *Scientific Reports*2022, 12, 773
 doi:10.1038/s41598-022-12153-0. 774

- 50. Hudson, A.W.; Barnes, A.J.; Bray, A.S.; Ornelles, D.A.; Zafar, M.A. Klebsiella Pneumoniae L- Fucose Metabolism Promotes Gastrointestinal Colonization and Modulates Its Virulence Determinants. *Infection and Immunity*2022, *90*, doi:10.1128/iai.00206-22.
- Lin, D.; Fan, J.; Wang, J.; Liu, L.; Xu, L.; Li, F.; Yang, J.; Li, B. The Fructose-Specific Phosphotransfer ase System of Klebsiella Pneumoniae Is Regulated by Global Regulator CRP and Linked to Virulence
 and Growth. *Infection and Immunity***2018**, *86*, doi:10.1128/iai.00340-18.